Compare Stocks: AIM, ATOS, TCRX, and NICXF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$0.18 -4.1%	$0.23	$0.17 ▼ $2.88	$5.71M	1.27	3.17 million shs	1.28 million shs
ATOS Atossa Genetics	$2.34 +3.1%	$2.39	$1.70 ▼ $19.35	$22.65M	1.27	58,314 shs	74,265 shs
NICXF Nicox	$0.30	$0.30	$0.25 ▼ $0.30	$20.67M	0.03	N/A	N/A
TCRX TScan Therapeutics	$0.32 +0.9%	$0.57	$0.29 ▼ $2.57	$21.52M	1.15	826,922 shs	144,290 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+7.26%	-7.67%	-20.47%	-32.96%	-93.02%
ATOS Atossa Genetics	+16.41%	+10.73%	-6.20%	+7.08%	-83.48%
NICXF Nicox	0.00%	0.00%	0.00%	0.00%	0.00%
TCRX TScan Therapeutics	+0.95%	-9.03%	-52.35%	-70.05%	-84.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$0.18 -4.1%	$0.23	$0.17 ▼ $2.88	$5.71M	1.27	3.17 million shs	1.28 million shs
ATOS Atossa Genetics	$2.34 +3.1%	$2.39	$1.70 ▼ $19.35	$22.65M	1.27	58,314 shs	74,265 shs
NICXF Nicox	$0.30	$0.30	$0.25 ▼ $0.30	$20.67M	0.03	N/A	N/A
TCRX TScan Therapeutics	$0.32 +0.9%	$0.57	$0.29 ▼ $2.57	$21.52M	1.15	826,922 shs	144,290 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+7.26%	-7.67%	-20.47%	-32.96%	-93.02%
ATOS Atossa Genetics	+16.41%	+10.73%	-6.20%	+7.08%	-83.48%
NICXF Nicox	0.00%	0.00%	0.00%	0.00%	0.00%
TCRX TScan Therapeutics	+0.95%	-9.03%	-52.35%	-70.05%	-84.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	2.50	Moderate Buy	$9.00	4,900.00% Upside
ATOS Atossa Genetics	2.20	Hold	$20.33	768.95% Upside
NICXF Nicox	2.00	Hold	N/A	N/A
TCRX TScan Therapeutics	2.13	Hold	$2.67	732.03% Upside

Current Analyst Ratings Breakdown

Latest AIM, ATOS, TCRX, and NICXF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2026	TCRX TScan Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	ATOS Atossa Genetics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$90K	60.88	N/A	N/A	($2.99) per share	-0.06
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
NICXF Nicox	$3.59M	5.76	N/A	N/A	$0.05 per share	6.00
TCRX TScan Therapeutics	$10.32M	2.10	N/A	N/A	$2.16 per share	0.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$13.96M	-$24.68	N/A	N/A	N/A	-15,021.05%	N/A	-143.02%	N/A
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
NICXF Nicox	-$24.23M	N/A	N/A	15.00	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)

Latest AIM, ATOS, TCRX, and NICXF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million
8/7/2026	Q2 2026	AIM AIM ImmunoTech	N/A	-$0.43	N/A	-$0.43	N/A	$0.03 million
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
NICXF Nicox	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	N/A	2.11	2.11
ATOS Atossa Genetics	N/A	5.69	5.69
NICXF Nicox	N/A	N/A	N/A
TCRX TScan Therapeutics	0.31	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
ATOS Atossa Genetics	12.74%
NICXF Nicox	N/A
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.95%
ATOS Atossa Genetics	9.80%
NICXF Nicox	N/A
TCRX TScan Therapeutics	6.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	21	30.44 million	30.15 million	Not Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
NICXF Nicox	28	68.92 million	N/A	Not Optionable
TCRX TScan Therapeutics	142	67.78 million	63.54 million	Not Optionable

AIM, ATOS, TCRX, and NICXF Headlines

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Consensus Price Target of $2.67

October 2 at 2:44 AM | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Stock Jumps 1% - Here's What Happened

October 2 at 1:41 AM | americanbankingnews.com

Korro Bio (NASDAQ:KRRO) & TScan Therapeutics (NASDAQ:TCRX) Financial Review

October 1 at 3:58 AM | americanbankingnews.com

TScan Therapeutics consensus price target decreased by 55.56% to $2.72

September 16, 2026 | msn.com

Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform

September 3, 2026 | msn.com

TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%

September 2, 2026 | rttnews.com

TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program

September 2, 2026 | msn.com

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

September 2, 2026 | benzinga.com

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)

August 13, 2026 | theglobeandmail.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results

August 12, 2026 | quiverquant.comQ

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026 | globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026 | globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...

June 23, 2026 | markets.businessinsider.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026 | globenewswire.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 3, 2026 | businesswire.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

June 2, 2026 | insidermonkey.com

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

May 22, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AIM, ATOS, TCRX, and NICXF Company Descriptions

AIM ImmunoTech NYSEAMERICAN:AIM

$0.18 -0.01 (-4.10%)

Closing price 04:10 PM Eastern

Extended Trading

$0.18 +0.00 (+1.11%)

As of 07:56 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Atossa Genetics NASDAQ:ATOS

$2.34 +0.07 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 -0.01 (-0.43%)

As of 07:30 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Nicox OTCMKTS:NICXF

$0.30 0.00 (0.00%)

As of 10/1/2026

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.

TScan Therapeutics NASDAQ:TCRX

$0.32 +0.00 (+0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.32 0.00 (-0.78%)

As of 06:59 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AIM, ATOS, TCRX, and NICXF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AIM, ATOS, TCRX, and NICXF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AIM, ATOS, TCRX, and NICXF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AIM, ATOS, TCRX, and NICXF Company Descriptions

AIM ImmunoTech NYSEAMERICAN:AIM

Atossa Genetics NASDAQ:ATOS

Nicox OTCMKTS:NICXF

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AIM, ATOS, TCRX, and NICXF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AIM, ATOS, TCRX, and NICXF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AIM, ATOS, TCRX, and NICXF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AIM, ATOS, TCRX, and NICXF Company Descriptions

AIM ImmunoTech NYSEAMERICAN:AIM

Atossa Genetics NASDAQ:ATOS

Nicox OTCMKTS:NICXF

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools